Gene and Cell Therapy: Shaping the Future of Medicine

TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.

An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.

Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.

The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.

The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.

The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.

The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.